MBB Public Markets I LLC Purchases New Stake in Abbott Laboratories $ABT

Key Points

• MBB Public Markets I LLC acquired 2,504 shares of Abbott Laboratories, valued at approximately $332,000, during the 1st quarter as reported in a Form 13F filing.
• Institutional investors and hedge funds hold 75.18% of Abbott Laboratories' stock, with Ascent Group LLC increasing its position by 71.6% in the same quarter.
• Abbott Laboratories reported quarterly earnings of $1.26 EPS, aligning with analysts' expectations, and set its FY 2025 guidance at 5.100-5.200 EPS.

MBB Public Markets I LLC bought a new stake in Abbott Laboratories (NYSE:ABT - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,504 shares of the healthcare product maker's stock, valued at approximately $332,000.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. Bank Pictet & Cie Europe AG raised its holdings in Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after acquiring an additional 2,774 shares in the last quarter. Guardian Wealth Advisors LLC NC boosted its position in Abbott Laboratories by 20.8% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 6,893 shares of the healthcare product maker's stock valued at $780,000 after purchasing an additional 1,187 shares during the last quarter. Jefferies Financial Group Inc. grew its stake in Abbott Laboratories by 163.5% in the fourth quarter. Jefferies Financial Group Inc. now owns 199,609 shares of the healthcare product maker's stock valued at $22,578,000 after purchasing an additional 123,843 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Abbott Laboratories by 1.6% during the 4th quarter. Janus Henderson Group PLC now owns 5,662,369 shares of the healthcare product maker's stock worth $640,479,000 after purchasing an additional 91,007 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Raymond James Financial decreased their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research note on Friday, July 18th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and lifted their price objective for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Mizuho upped their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, July 16th. Leerink Partners started coverage on Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Finally, William Blair raised Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $144.47.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Stock Performance

NYSE:ABT traded down $2.56 during mid-day trading on Wednesday, hitting $129.39. 7,392,932 shares of the stock were exchanged, compared to its average volume of 4,846,492. The firm's 50-day simple moving average is $130.43 and its 200 day simple moving average is $131.35. The stock has a market capitalization of $225.20 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 2.50 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were issued a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's payout ratio is currently 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.